<DOC>
	<DOCNO>NCT01352182</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics pioglitazone determine effect inflammatory biomarkers pioglitazone patient severe sepsis septic shock .</brief_summary>
	<brief_title>Pharmacokinetic Biomarker Study Pioglitazone Adolescents With Severe Sepsis Septic Shock</brief_title>
	<detailed_description>Severe sepsis major cause morbidity mortality among adults child . Few clinical trial demonstrate clinical benefit sepsis . Severe sepsis systemic inflammatory syndrome response infection associate acute organ dysfunction . The nuclear receptor peroxisome proliferator-activated receptor-gamma ( PPARg ) involve regulation sepsis-induced inflammatory response . The central hypothesis pioglitazone reduce inflammatory response child severe sepsis septic shock .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Weight range 30 less equal 90kg Have know suspected infection meet criterion severe sepsis septic shock define accord International Pediatric Sepsis Consensus Conference guideline Are moribund state death perceive imminent Have advance directive resuscitate order withhold lifesustaining Have history cyanotic heart disease congestive heart failure Have serum transaminase level ( ALT ) exceed 2.5 time upper limit normal ( &gt; 112 unit/L ) Are become pregnant Are already history take pioglitazone rosiglitazone Have type 1 2 diabetes Have total body weight 30 kg 90 kg Have serious condition , addition sepsis , opinion investigator would compromise participant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>